Search CTL/CD8+ T-Cell Epitope Database

Found 1 matching record:

Displaying record number 58812

Download this epitope record as JSON.

HXB2 Location	Gag(147-155) p24(15-23) DNA(1228..1254)	Gag Epitope Map
Author Location	Gag(147-155)
Epitope	ISPRTLNAW	Epitope Alignment
		Show epitope variants
Epitope Name	ISW9
Subtype	B
Species (MHC/HLA)	human(B*57:01)
Immunogen	HIV-1 infection
Patient MHC/HLA	A*01:01, A*03:01, B*27:05, B*57:01; A*01:01, A*24:02, B*40:02, B*57:01; A*24:02, A*32:01, B*40:02, B*57:01; A*01:01, A*02:01, B*51:01, B*57:01; A*01:01, A*01:01, B*08:01, B*57:01; A*03:01, A*24:02, B*35:01, B*57:01
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	rate of progression

Notes

• High resolution evolutionary and immunological data were used to follow 6 ART-naive, HLA-B*5701 positive subjects longitudinally over 7 years. Low risk progressors (LRPs) had more polyfunctional CTL responses to both TW10 (TSTLQEQIGW) and QW9 (QASQEVKNW) epitopes and produced early IL-2, resulting in higher, defining CD4+ baseline counts. Conversely, high risk progressors (HRPs) had more substitutions, less polyfunctionality of CTL response, resulting in lower CD4+ baseline counts.
• Substitutions occurred more frequently in flanking regions of HLA-B*5701-restricted epitopes than within and this was true of both LRPs and HRPs.
• Flanking mutations for ISW9 (A|ISPRTLNAW|V) were similar for both LRPs and HRPs. Except for patient2 (P2), all subjects had at least one mutation in ISW9.

References

Norstrom2012 Melissa M. Norström, Marcus Buggert, Johanna Tauriainen, Wendy Hartogensis, Mattia C. Prosperi, Mark A. Wallet, Frederick M. Hecht, Marco Salemi, and Annika C. Karlsson. Combination of Immune and Viral Factors Distinguishes Low-Risk Versus High-Risk HIV-1 Disease Progression in HLA-B*5701 Subjects. J. Virol., 86(18):9802-9816, Sep 2012. PubMed ID: 22761389. Show all entries for this paper.